^
BIOMARKER:

TP53 deletion

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
TP53 deletion
CLL
idelalisib
Sensitive: A2 - Guideline
TP53 deletion
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 deletion
CLL
rituximab
Sensitive: A2 - Guideline
TP53 deletion
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
TP53 deletion
Prostate Cancer
abiraterone acetate
Resistant: B - Late Trials
TP53 deletion
Prostate Cancer
enzalutamide
Resistant: B - Late Trials
TP53 deletion
CLL
venetoclax + obinutuzumab
Sensitive: B - Late Trials
TP53 deletion
CLL
venetoclax + obinutuzumab
Sensitive: C2 – Inclusion Criteria
TP53 deletion
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
TP53 deletion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
TP53 deletion
Mantle Cell Lymphoma
venetoclax + rituximab + ibrutinib
Sensitive: C3 – Early Trials
ASH 2021 - 4 weeks
TP53 deletion
CLL
ONC212
Sensitive: D – Preclinical
TP53 deletion
CRC
sirolimus + IPI-504
Sensitive: D – Preclinical
TP53 deletion
NSCLC
sirolimus + IPI-504
Sensitive: D – Preclinical
TP53 deletion
Mantle Cell Lymphoma
venetoclax
Resistant: D – Preclinical